Minidiab 5 mg
Each tablet contains 5 mg GlipizideCompany Name
CID/Pfizer
Therapeutic Group
SULPHONYLUREA A-DIABS
Pharmaceutical form
Tablet
Package
Box of 30 scored tablets
Indications
Maturity- onset diabetes, not manageable by diet alone.
Warning & Precautions
Oral hypoglycaemic agents belonging the sulphonylureas category should only be used in patients with maturity-onset, symptomatic diabetes mellitus, not ketogenic, not manageable by dietary measures alone, and not requiring insulin treatment. Should hypoglycaemia occur (see side effects) administer carbohydrates (sugar) ;in more serious cases in which, very rarely, may lead to the loss of consciousness, a slow i.v infusion of glucose solution should be administered. In patients with traumas, after surgery,infectious or febrile diseases, it may be necessary to administer insulin temporarily in order to maintain an adequate metabolic control. In patients on sulphonylurea therapy, the possibility of antabuse-like reactions after ingestion of alcohol drinks should be borne in mind . Patients should follow closely their physician,s prescription as regards diet, dosage and schedule for taking the drug, and should be taught to recognise promptly the early symptoms of hypoglycaemia, that generally are headache; irritability, sleep disorders, tremor and heavy sweating, so they can contact a doctor in good time.
Product Type
human
Dosage
Dosage should be adapted to patients individually, on the basis of periodic tests of glycosuria and blood sugar. Normal blood sugar can be managed with doses of 2.5 to 20mg. of Minidiab ( ½ to 4 tablets daily ) . Patients treated for the first time : Start with ½ - 1 tablet daily, and increase the dose as necessary until the patient is managed satisfactorily . Patients already treated with oral hypoglycaemic agents: The dosage depends on each patient's clinical metabolic condition and on what treatment was given before. It is anyway advisable to start with low dosage, increasing them gradually until a satisfactory balance is reached . These patients need close surveillance, and sometimes it is advisable to leave a brief period between the end of previous treatment and the start of Minidiaib therapy. Patients treated with insulin: In some cases, daily insulin requirements can be cut down when Minidiab is added to the regimen ; however, during the first period of treatment the patient's blood sugar should be frequently checked . The daily dosage of Minidiab should be split into two or more doses, to be taken immediately before the main meals .
Adverse Reactions
Although rare, hypoglycaemic episodes may occur during treatment with sulphonylureas, especially in debilitated or elderly subjects, after unusual physical exertion when food intake is irregular or alcoholic beverages are taken, and when kidney and/or liver function is impaired (see warnings). Very occasional is the appearance of gastro-enteric disturbances (such as nausea or a sense of epigastric fullness), and headache. These disturbances are usually linked to the dosage and normally regress when the dose is reduced, as long as this can be done compatibly with the maintenance of the metabolic balance. Patients treated with sulphonylureas have occasionally complained of transient allergic-type skin reaction, which normally disappear as therapy continues. Very rarely, alterations to the haemopoietic system have been reported, generally reversible.
Contra Indications
Like other sulphonylureas, Minidiab is contraindicated in : Insulin-Dependent diabetes, keto - acidosis diabetes, diabetic pre-coma or coma, pregnancy, subjects with severely impaired kidney or liver function, adrenal insufficiency, cases of confirmed individual hypersensitivity to the drug. In latent diabetes or prediabetic states, the use of sulphonylureas is not advisable .
Drug Interactions
- The hypoglycaemic of Minidiab activity of the sulphonylureas may be increased by dicoumarol and derivatives, by monoamine oxidase inhibitors, sulphonamides , phenylbutazone , and derivatives, chloramphenicol, cyclophosphamide , probenecid, pheniramidol and salicylates . - The hypoglycaemic of Minidiab effect may be reduced by concomitant use of adrenaline, corticosteroids, oral contraceptives and thiazide diuretics.Care must also be used when beta-blockers are administered at the same time. Keep out of reach of children .
No comments:
Post a Comment